Archive WILEX Press Releases

Selected press releases of the former years can be found here.

13 October 2008

WILEX releases 9-month Financial Report 2008: Progress in development projects

17 September 2008

Additional information regarding yesterday's voting rights announcement

11 August 2008

WILEX starts patient recruitment in Phase II breast cancer trial with its uPA inhibitor MESUPRON®* (WX-671)

24 July 2008

Patient recruitment in Phase II trial with MESUPRON®* (WX-671) in pancreatic cancer patients successfully completed

14 July 2008

WILEX reports successful first half year 2008

03 July 2008

Phase III ARISER study with RENCAREX®*: patient recruitment successfully completed

06 June 2008

WILEX and IBA enter into worldwide marketing, distribution and sales agreement on REDECTANE®* (CA9-SCAN)

19 May 2008

Patient recruitment started in Phase III registration trial with CA9-SCAN

10 April 2008

WILEX reports successful first quarter 2008

20 February 2008

WILEX reports a successful financial year 2007 – positive outlook for 2008

11 February 2008

FDA issues Special Protocol Assessment (SPA) for pivotal Phase III trial with CA9-SCAN

28 January 2008

WILEX receives US FDA approval (IND) for clinical Phase II trial with its uPA inhibitor WX-671 in metastatic breast cancer

25 January 2008

Phase I study with uPA inhibitor WX-UK1 successfully completed